Back

Targeting the PKR1 pathway and the ROS/NRF/PK2 axis for cardioprotection and biomarker discovery in anthracycline therapy

20 June 2026 (13:15 - 14:15)
Organised by: Logo
Congress Presentation Part of: Mechanisms and investigational therapies of anthracycline cardiotoxicity Research and New Technology Delegates Premium Access ESC Cardio-Oncology 2026 Council of Cardio-Oncology

About the speaker

Photo
Professor Canan Nebigil

INSERM, University of Strasbourg, CRBS, Strasbourg (France)

4 More presentations in this session

Presentation thumbnail
HDAC inhibition via suberoylanilide hydroxamic acid (SAHA) ameliorates doxorubicin-induced cardiotoxicity
Mrs B. Eksi (Heidelberg, DE)
Abstract Slides
Presentation thumbnail
Hemopexin mitigates doxorubicin cardiotoxicity by preserving cardiac metabolism while maintaining antitumor efficacy in a mouse model of breast cancer
Doctor G. Guerra (Turin, IT)
Abstract Slides
Presentation thumbnail
Interleukin-1 receptor 8 deficiency enhances the anti-tumour activity of doxorubucin and reduces cardiotoxicity
Doctor F. Scavello (Rozzano, IT)
Abstract Slides
Presentation thumbnail
ATNFAIP8--dependent survival axis protects cardiomyocytes from anthracycline-induced cardiotoxicity
Professor Y. Liu (Tainan, TW)
Abstract Slides

Access the full session

Session thumbnail
Mechanisms and investigational therapies of anthracycline cardiotoxicity

The Event

Event poster

ESC Cardio-Oncology 2026

20 June 2026 13:15 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources